ALNY - Alnylam Pharmaceuticals, Inc.
79.50 0.00 (0.00%)
After hours: 6:31PM EST
| Previous Close | 76.79 |
| Open | 77.88 |
| Bid | 69.00 x 800 |
| Ask | 95.00 x 3000 |
| Day's Range | 77.74 - 81.04 |
| 52 Week Range | 63.57 - 153.99 |
| Volume | 498,599 |
| Avg. Volume | 890,342 |
| Market Cap | 8.032B |
| Beta (3Y Monthly) | 3.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.97 |
| Earnings Date | Feb 6, 2019 - Feb 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 122.59 |
Zacks•2 days ago5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
- Business Wire•3 days ago
Alnylam Announces Settlement of Litigation with Silence Therapeutics
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multiple countries. Under terms of the global settlement, Silence will receive a low royalty on annual net sales of ONPATTRO in the EU only, with tiered royalties of 0.33 percent to 1.0 percent through 2023. Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products, whether commercialized by Alnylam or a collaborator or licensee (including ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and all other investigational therapeutics in Alnylam’s current and future pipeline).
- Insider Monkey•4 days ago
Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY)
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- The Wall Street Journal•5 days ago
[$$] Moderna IPO Marks Milestone for New Biotech Market
Inc.’s $604.3 million initial public offering is a highlight in a big year for the new field of messenger-RNA therapeutics. Moderna, whose drugs and vaccines are designed to cause cells to produce molecules that treat or prevent disease, went public at $23 a share late Thursday and began trading Friday at $22. Alnylam, valued at $7.38 billion, this year became the first to win U.S. approval for a product in a class of treatments, known as siRNA therapy, which silence disease-causing RNA molecules.
Bloomberg•5 days agoModerna’s Rich IPO Valuation Raises the Stakes for Investors
(Bloomberg Opinion) -- Moderna Inc. could have picked a better time to go public.
- GlobeNewswire•6 days ago
Recent Analysis Shows Microsoft, Alnylam Pharmaceuticals, F5 Networks, Green Plains Partners LP, Itron, and Progress Software Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•7 days ago
Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announces it is hosting its R&D Day in New York City today. During the event, the Company plans to discuss its pipeline goals for 2019, focusing on five late-stage investigational programs advancing toward potential commercialization. The Company will also discuss commercial execution with ONPATTRO™ (patisiran).
- Investor's Business Daily•13 days ago
Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis
Dow Jones' component Pfizer will take the lion's share of the amyloidosis treatment market — leaving Alnylam and Ionis to duke it out for the remainder, an analyst says.
- ACCESSWIRE•13 days ago
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 30, 2018 / U.S. markets closed lower on Thursday as investors await details from this weekend's trade meeting between President Trump and Chinese President Xi Jinping. ...
- Business Wire•13 days ago
Alnylam to Webcast R&D Day
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Company’s website, www.alnylam.com, on the morning of December 6, 2018.
- Zacks•15 days ago
Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate
Alnylam (ALNY) and Vir commence phase I/II study for VIR-2218 for the treatment of chronic HBV infection.
- Simply Wall St.•15 days ago
Why Alnylam Pharmaceuticals Inc’s (NASDAQ:ALNY) CEO Pay Matters To You
John Maraganore has been the CEO of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) since 2002. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, Read More...
- Business Wire•16 days ago
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Alnylam overstated the efficacy of its Onpattro (patisiran) lipid complex injection, and also inflated the safety of the treatment.
- Business Wire•17 days ago
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The commencement of first-in-human dosing marks the first clinical use of Alnylam’s Enhanced Stabilization Chemistry-Plus (ESC+) GalNAc conjugate delivery platform and the start of Vir’s first global development program. VIR-2218 was originated by Alnylam as ALN-HBV02 and was licensed to Vir, which will conduct its clinical development.
- GlobeNewswire•17 days ago
DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Alnylam overstated the efficacy of its Onpattro (patisiran) lipid complex injection, and also inflated the safety of the treatment.
- GlobeNewswire•17 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ALNY, CHGG, CWH and DY
NEW YORK, Nov. 25, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•17 days ago
ALNY NOV 26 DEADLINE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action
NEW YORK, Nov. 25, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February.
- GlobeNewswire•17 days ago
MONDAY DEADLINE: Kaskela Law LLC Announces Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm – ALNY
RADNOR, Pa., Nov. 25, 2018 -- Kaskela Law LLC announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (“Alnylam” or the.
- ACCESSWIRE•18 days ago
TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 24, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2018 and September 12, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2018.
- ACCESSWIRE•18 days ago
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. – ALNY
NEW YORK, NY / ACCESSWIRE / November 24, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ...
- ACCESSWIRE•19 days ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, NY / ACCESSWIRE / November 23, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Alnylam stock or options between February 15, 2018 and September 12, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ALNY. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.
- Business Wire•19 days ago
DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Alnylam overstated the efficacy of its Onpattro (patisiran) lipid complex injection, and also inflated the safety of the treatment.
- GlobeNewswire•19 days ago
SHAREHOLDER ALERT: APOG TGTX ALNY ACHC JT HON DY ALGN RYAAY MGI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Nov. 23, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- CNBC Videos•13 days ago
Alnylam CEO on drug prices: Has to be some type of reward...
Alnylam CEO John Maraganore, discusses his company's share price decline and the very high price of his company's drug Onpattro.
